Selecta Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Selecta Biosciences, Inc.
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations.
Analysts have mixed opinions about whether a Phase IIb study of SEL-212, which Selecta recently licensed to Sobi, helps the drug’s commercial potential versus Horizon’s Krystexxa.
Swedish Orphan Biovitrum’s financial performance in the second quarter was held back by COVID-19 related events, but it has left its financial guidance unchanged for 2020.
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.